IN2014MU01248A - - Google Patents
Info
- Publication number
- IN2014MU01248A IN2014MU01248A IN1248MU2014A IN2014MU01248A IN 2014MU01248 A IN2014MU01248 A IN 2014MU01248A IN 1248MU2014 A IN1248MU2014 A IN 1248MU2014A IN 2014MU01248 A IN2014MU01248 A IN 2014MU01248A
- Authority
- IN
- India
- Prior art keywords
- stabilizer
- surfactant
- buffer
- pharmaceutical composition
- relates
- Prior art date
Links
- 239000000872 buffer Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1248MU2014 IN2014MU01248A (hu) | 2014-04-02 | 2015-02-18 | |
| CA2944330A CA2944330A1 (en) | 2014-04-02 | 2015-02-18 | Liquid pharmaceutical composition of adalimumab |
| PCT/IN2015/000092 WO2015151115A1 (en) | 2014-04-02 | 2015-02-18 | Liquid pharmaceutical composition of adalimumab |
| US15/301,421 US10688187B2 (en) | 2014-04-02 | 2015-02-18 | Liquid pharmaceutical composition of adalimumab |
| EP15774333.7A EP3125928A4 (en) | 2014-04-02 | 2015-02-18 | Liquid pharmaceutical composition of adalimumab |
| US16/894,196 US20200405864A1 (en) | 2014-04-02 | 2020-06-05 | Liquid pharmaceutical composition of adalimumab |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1248MU2014 IN2014MU01248A (hu) | 2014-04-02 | 2015-02-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MU01248A true IN2014MU01248A (hu) | 2015-10-09 |
Family
ID=54239505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1248MU2014 IN2014MU01248A (hu) | 2014-04-02 | 2015-02-18 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10688187B2 (hu) |
| EP (1) | EP3125928A4 (hu) |
| CA (1) | CA2944330A1 (hu) |
| IN (1) | IN2014MU01248A (hu) |
| WO (1) | WO2015151115A1 (hu) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10426832B2 (en) | 2014-05-23 | 2019-10-01 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
| US10426833B2 (en) | 2014-05-23 | 2019-10-01 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
| US10493152B2 (en) | 2014-05-23 | 2019-12-03 | Fresenius Kabi Deutschland Gmbh | Adalimumab formulations |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20217249B (en) * | 2016-06-30 | 2021-04-26 | Inc Celltrion | Stable liquid pharmaceutical preparation |
| EP4467565A3 (en) | 2016-12-21 | 2025-03-12 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| ES2933808T3 (es) | 2017-01-11 | 2023-02-14 | Celltrion Inc | Fórmula líquida estable |
| AU2018236651B2 (en) * | 2017-03-16 | 2020-12-10 | Lg Chem, Ltd. | Liquid formulation of anti-TNF alpha antibody |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| US20230203147A1 (en) * | 2019-03-18 | 2023-06-29 | Alvotech Hf | Aqueous formulations of tnf-alpha antibodies in high concentrations |
| WO2021067775A1 (en) * | 2019-10-02 | 2021-04-08 | Alamab Therapeutics, Inc. | Anto-connexin antibody formulations |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| CN103275221B (zh) | 1996-02-09 | 2016-08-17 | 艾伯维生物技术有限公司 | 结合人TNFα的人抗体 |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| WO2002013860A1 (fr) | 2000-08-11 | 2002-02-21 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilisees contenant un anticorps |
| WO2003072060A2 (en) | 2002-02-27 | 2003-09-04 | Immunex Corporation | Polypeptide formulation |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| US8420081B2 (en) | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| US8821865B2 (en) * | 2010-11-11 | 2014-09-02 | Abbvie Biotechnology Ltd. | High concentration anti-TNFα antibody liquid formulations |
| EP2771033A4 (en) * | 2011-10-28 | 2016-02-17 | Integritybio Inc | PROTEIN FORMULATIONS CONTAINING AMINO ACIDS |
| WO2013164837A1 (en) | 2012-03-07 | 2013-11-07 | Cadila Healthcare Limited | Pharmaceutical formulations of tnf-alpha antibodies |
| FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
| KR102362829B1 (ko) | 2012-09-07 | 2022-02-15 | 코히러스 바이오사이언시즈, 인코포레이티드 | 아달리무맙의 안정한 수성 제형 |
| EP3050557A1 (en) | 2014-05-23 | 2016-08-03 | Ares Trading S.A. | Liquid pharmaceutical composition |
| TW201636047A (zh) | 2015-01-28 | 2016-10-16 | 麥博賽恩斯有限公司 | 抗－ＴＮＦ－α抗體之醫藥調配物 |
-
2015
- 2015-02-18 EP EP15774333.7A patent/EP3125928A4/en not_active Withdrawn
- 2015-02-18 CA CA2944330A patent/CA2944330A1/en not_active Abandoned
- 2015-02-18 WO PCT/IN2015/000092 patent/WO2015151115A1/en active Application Filing
- 2015-02-18 IN IN1248MU2014 patent/IN2014MU01248A/en unknown
- 2015-02-18 US US15/301,421 patent/US10688187B2/en not_active Expired - Fee Related
-
2020
- 2020-06-05 US US16/894,196 patent/US20200405864A1/en not_active Abandoned
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10426832B2 (en) | 2014-05-23 | 2019-10-01 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
| US10426833B2 (en) | 2014-05-23 | 2019-10-01 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
| US10493152B2 (en) | 2014-05-23 | 2019-12-03 | Fresenius Kabi Deutschland Gmbh | Adalimumab formulations |
| US10729769B2 (en) | 2014-05-23 | 2020-08-04 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
| US10772961B2 (en) | 2014-05-23 | 2020-09-15 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
| US11707524B2 (en) | 2014-05-23 | 2023-07-25 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
| US11712471B2 (en) | 2014-05-23 | 2023-08-01 | Fresenius Kabi Deustschland GmbH | Liquid pharmaceutical composition |
| US11752209B2 (en) | 2014-05-23 | 2023-09-12 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
| US11752208B2 (en) | 2014-05-23 | 2023-09-12 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
| US12109267B2 (en) | 2014-05-23 | 2024-10-08 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3125928A4 (en) | 2017-11-29 |
| US20200405864A1 (en) | 2020-12-31 |
| US10688187B2 (en) | 2020-06-23 |
| US20170106090A1 (en) | 2017-04-20 |
| EP3125928A1 (en) | 2017-02-08 |
| WO2015151115A1 (en) | 2015-10-08 |
| CA2944330A1 (en) | 2015-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276695B (en) | Antibodies, pharmaceutical preparations and their uses | |
| PH12018500894A1 (en) | Aqueous pharmaceutical formulation comprising anti-pd-l1 antibody avelumab | |
| IL262497A (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| ZA201806576B (en) | Antibodies, pharmaceutical compositions and methods | |
| ZA201701168B (en) | Antibodies, compositions, and uses | |
| IN2014MU01248A (hu) | ||
| IL255443A0 (en) | Anti-cgrp antibody formulation | |
| MX2020009649A (es) | Anticuerpos monoclonales contra bcma. | |
| PH12017500861A1 (en) | Anti-interleukin-33 antibodies and uses thereof | |
| CL2016002772A1 (es) | Composiciones de insulina de rápida acción | |
| SG10201803042PA (en) | Anti-tim-3 antibodies | |
| MX2019007021A (es) | Anticuerpos il-11ra. | |
| PH12016501873A1 (en) | Anti-influenza b virus hemagglutinin antibodies and methods of use | |
| PH12016501763A1 (en) | Multispecific antibodies | |
| IL257956A (en) | New carbohydrate antibodies, pharmaceutical preparations and their uses | |
| EA201790380A1 (ru) | Ингибиторы mk2 и их применения | |
| MY181175A (en) | Therapeutic hpv16 vaccines | |
| ZA201800804B (en) | Novel anti-human gpvi antibodies and uses thereof | |
| IL237852A0 (en) | Antibodies against amphigoline, medical preparations containing them and their use | |
| MX2016016233A (es) | Anticuerpos anti-lgr5 y sus usos. | |
| RU2015118269A (ru) | Универсальная бутылка | |
| UA99992U (ru) | 2-оксо-4-фенил-5-циано-1,2,3,4-тетрагидропиридин-6-тиолат n-метилморфолиния | |
| TN2014000522A1 (fr) | لوح مدرسي بوجهين | |
| BR302014000338S1 (pt) | Configuração aplicada em garrafa. | |
| BR302014000025S1 (pt) | Configuração aplicada em frasco. |